AGT-1

Drug Profile

AGT-1

Latest Information Update: 04 Nov 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advanced Biotherapy
  • Developer Advanced Biotherapy; Brown University Medical School; GroupMed CRO; Russian Academy of Medical Sciences; Russian State Medical University
  • Class Antibodies
  • Mechanism of Action Immunosuppressants; Interferon alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 04 Nov 2003 Discontinued - Clinical-Phase-Unknown for Multiple sclerosis in Russia (unspecified route)
  • 04 Nov 2003 Discontinued - Clinical-Phase-Unknown for Rheumatoid arthritis in Russia (Injection)
  • 04 Nov 2003 Discontinued - Clinical-Phase-Unknown for Systemic lupus erythematosus in Russia (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top